Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE0005227235
Thu, 05.10.2023
Biotest AG
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)
Increase of the EBIT guidance
Dreieich, 05 October 2023. Against the background of the agreements concluded between Biotest AG, Dreieich, Germany and Grifols, S.A., Barcelona, Spain, which include a technology transfer and licensing agreement [ … ]
Thu, 05.10.2023
Biotest AG
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)
Peter Janssen appointed new Chairman of the Board of Biotest AG
Dreieich, 5 October 2023. In its meeting today, the Supervisory Board of Biotest AG appointed Mr. Peter Janssen (57) as Chairman of the Management Board of Biotest AG with effect [ … ]
Fri, 28.04.2023
Biotest AG
Ad hoc NOTICE
Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)
Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised
Dreieich, 28 April 2023. The Supervisory Board approved the signing and execution of several agreements by the Board of Management to further strengthen the c [ … ]
Fri, 28.04.2023
Biotest AG
Ad hoc NOTICE
Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)
Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised
Dreieich, 28 April 2023. The Supervisory Board approved the signing and execution of several agreements by the Board of Management to further strengthen the c [ … ]
Thu, 09.02.2023
Biotest AG
Ad hoc NOTICE
Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)
Biotest significantly exceeds EBIT guidance 2022
Dreieich, 09 February 2023. According to preliminary and not yet audited figures, the Biotest Group slightly increased its revenues to € 516.1 million in the financial year 2022, compared to € 515.6 million in [ … ]
Thu, 09.02.2023
Biotest AG
Ad hoc NOTICE
Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)
Biotest significantly exceeds EBIT guidance 2022
Dreieich, 09 February 2023. According to preliminary and not yet audited figures, the Biotest Group slightly increased its revenues to € 516.1 million in the financial year 2022, compared to € 515.6 million in [ … ]
Wed, 16.02.2022
Biotest AG
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest exceeds Revenue guidance 2021Dreieich, 16 February 2022. According to preliminary and not yet audited figures, Biotest AG increased its revenues by more than 6.5 % to € 515.6 million in fiscal year 2021, compared to € 484.2 million in the previous year [ … ]
Fri, 07.01.2022
Biotest AG
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer
Dreieich, 7 January 2022. In accordance with Sections 23 para. 1 sentence 1 no. 2, no. 4 of the German Securities Acquisition and Takeover Act (WpÜG), Grifi [ … ]
Wed, 08.12.2021
Biotest AG
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)Dreieich, 08 Dezember 2021. Due to the changing market environment for the plasmatic coagulation factor VIII, the Supervisory Board of Biotest Aktiengesellschaft decided in its meeting today that Biotest will only produce factor VIII in a sales-correlated mann [ … ]
Fri, 17.09.2021
Biotest AG
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AGDreieich, 17 September 2021. Grifols S.A. announced today its decision to make a voluntary public takeover offer for all out-standing ordinary and preference sha [ … ]